RZLT
$2.56
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
Recent News
Rezolute’s Phase 3 sunRIZE Study for Ersodetug Fails to Meet Primary and Secondary Endpoints Despite Analyst Backing
Rezolute Inc. (NASDAQ:RZLT) is one of the best biotech penny stocks to buy according to analysts. On December 11, Rezolute released topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism/HI. The study, which included 63 participants aged 3 months to 45 years across more than a dozen countries, did […]
Insiders Made Their Bets in 2025—These Were the Top 5 Stocks They Bought
Insiders bought these stocks heavily in 2025, but investors should be wary; only some of them are good buys for 2026 portfolios.
Chief Financial Officer of Rezolute Daron Evans Buys 21% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the Rezolute, Inc. ( NASDAQ:RZLT ) Chief Financial...
RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know
Rezolute shares collapse 79% so far in December after a phase III hyperinsulinism study of its only pipeline candidate miss primary and key secondary endpoints.
Down 81.8% in 4 Weeks, Here's Why Rezolute (RZLT) Looks Ripe for a Turnaround
Rezolute (RZLT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.